ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "TNF-blocking Antibody"

  • Abstract Number: 068 • 2023 Pediatric Rheumatology Symposium

    Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)

    Ilaria Maccora1, Arjun Sood2, Grant Schulert3, Megan Quilan-Water3, Alexandra Duell3, Jennifer Huggins3, Tiffany Nguyen2, Cameron Sapp2, Sumit Sharma4, Srivastaval Sunil4 and Sheila Angeles-Han5, 1IRCCS Meyer Children’s Hospital, Rheumatology Unit, Florence, Italy, 2Cincinnati Eye Institute, Cincinnati, OH, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Cole Eye Institute, Cleveland Clinic, Cleveland, OH, 5Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Pediatric uveitis is commonly associated with rheumatic disease and can lead to sight-threatening complications if not properly treated. Systemic immunomodulatory therapy has dramatically changed…
  • Abstract Number: 0139 • ACR Convergence 2022

    A Clinical Study Designed to Support a Demonstration of Interchangeability Between AVT02 and Reference Adalimumab (Humira®)

    Steven Feldman1, Heimo stroissnig2, Richard Kay3, Joanna Sobierska4, Roshan Dias4, Eric Guenzi5, Hendrik Otto2, Halimuniyazi Haliduola2, Abid Sattar6, Ruth Ruffieux4, Matjaz Steijger4 and Fausto Berti4, 1Wake Forest School of Medicine, Winston-Salem, NC, 2Alvotech, Jülich, Germany, 3RK Statistics, Bakewell, United Kingdom, 4Alvotech, Zürich, Switzerland, 5UGA Biopharma, Bonn, Germany, 6Alvotech, London, United Kingdom

    Background/Purpose: To support a demonstration of interchangeability of proposed biosimilar AVT02 and Humira® (reference adalimumab).Methods: Participants with chronic plaque psoriasis were selected for the study…
  • Abstract Number: 1418 • ACR Convergence 2022

    Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry

    Colleen Correll1, Scott Stryker2, David Collier3, Anne Dennos4, Stephen Balevic5, Thomas Phillips5 and Tim Beukelman6, 1University of Minnesota, Minneapolis, MN, 2Amgen Inc., San Francisco, CA, 3Amgen Inc., Simi Valley, CA, 4Duke University, Durham, NC, 5Duke Clinical Research Institute, Durham, NC, 6Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL

    Background/Purpose: Juvenile psoriatic arthritis (JPsA) constitutes ~5% of juvenile idiopathic arthritis (JIA). Several therapeutics are available for JPsA; however, given the low JPsA incidence, important…
  • Abstract Number: 0254 • ACR Convergence 2022

    Lipids and Vascular Inflammation in Patients with RA Using Triple Therapy vs Methotrexate + TNFi: A Secondary Analysis of the TARGET Randomized Active Comparator Trial

    Katherine Liao1, Jon Giles2, Pamela Rist1, Robert Glynn1, Leah Santacroce1, Paul Ridker1, Ahmed Tawakol3, Joan Bathon2 and Daniel Solomon1, 1Brigham and Women's Hospital, Boston, MA, 2Columbia University, New York, NY, 3Massachusetts General Hospital, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) treatments are known to cause complex changes in lipids, in part by controlling disease activity. While there are robust data on…
  • Abstract Number: 1505 • ACR Convergence 2022

    Blue-collar Workers with Psoriatic Arthritis: Disease Activity, Work Disability and Response to Biologics

    Nina Colla1, Julia-Tatjana Maul2, Burkhard Moeller3, Michael Nissen4, Nikhil Yawalkar5, Eleftherios Papagiannoulis6, Oliver Distler1, Adrian Ciurea7 and Raphael Micheroli8, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 2Department of Dermatology and Venereology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 3Inselspital - University Hospital Bern, Bern, Switzerland, 4Hopitaux Universitaires de Genève, Geneva, Switzerland, 5Department of Dermatology, University Hospital Inselspital Bern, Bern, Switzerland, 6Statistics Group, SCQM Foundation, Zurich, Switzerland., Zürich, 7University Hospital Zurich, Zürich, Switzerland, 8University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland

    Background/Purpose: Biomechanical stress is a possible trigger of inflammation in psoriatic arthritis (PsA). The influence of physically demanding occupations on this potential association has not…
  • Abstract Number: 0302 • ACR Convergence 2022

    Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis

    SE RIM CHOI1, Anna Shin2, You-Jung Ha2, Yun Jong Lee2, Eun Bong Lee1 and Eun Ha Kang2, 1Seoul National University Hospital, Seoul, Republic of Korea, 2Seoul National University Bundang Hospital, Seongnam, Republic of Korea

    Background/Purpose: To compare infectious risk between JAK inhibitors (JAKi) versus TNF inhibitors (TNFi) among patients with rheumatoid arthritis (RA) in Korea. Methods: Using 2009-2019 Korea…
  • Abstract Number: 1510 • ACR Convergence 2022

    Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of Tumour Necrosis Factor Inhibitors in Axial Spondyloarthritis – Data from 14 European Countries

    Gareth Jones1, Ovidiu Rotariu1, Brigitte Michelsen2, Bente Glintborg3, Bjorn Gudbjornsson4, Arni Geirsson5, Heikki Relas6, Pia Isomäki7, Jakub Závada8, Karel Pavelka9, Ziga Rotar10, Matija Tomsic10, Michael Nissen11, Adrian Ciurea12, Catalin Codreanu13, Johan Karlsson Wallman14, Eirik Kristianslund15, Simon Rasmussen16, Lykke Ørnbjerg17, Maria José Santos18, Mikkel Østergaard19, Merete L Hetland20 and Gary Macfarlane1, 1University of Aberdeen, Aberdeen, Scotland, United Kingdom, 2Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Kristiansand, Norway, 3Rigshospitalet, Glostrup, Virum, Denmark, 4Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, 5Department of Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, 6Rheumatology, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland, 7Centre for Rheumatology, Tampere University Hospital, Tampere, Finland, 8Institute of Rheumatology, Prague, Czech Republic, 9Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, 10University Medical Centre Ljubljana, Ljubljana, Slovenia, 11Hopitaux Universitaires de Genève, Geneva, Switzerland, 12University Hospital Zurich, Zürich, Switzerland, 13Center for Rheumatic Diseases, Bucharest, Romania, 14Lund University and Skane University Hospital, Hjarup, Sweden, 15Diakonhjemmet Hospital, Division of Rheumatology and Research, Oslo, Norway, 16Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, 17Copenhagen Center for Arthritis Research, Glostrup, Denmark, 18Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal, 19Rigshospitalet, University of Copenhagen, Glostrup, Denmark, 20Rigshospitalet, Glostrup, Denmark

    Background/Purpose: In axial spondyloarthritis (axSpA) much attention has been focused on pharmacological management, including tumour necrosis factor inhibitors (TNFi), as a means to reducing inflammation,…
  • Abstract Number: 0306 • ACR Convergence 2022

    Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry

    Gabriela Schmajuk1, Nevin Hammam2, Jing Li3, David Collier4, Greg Kricorian5 and Scott Stryker6, 1UCSF / SFVA, San Francisco, CA, 2Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA, 3University of California, San Francisco, San Francisco, CA, 4Amgen Inc., Simi Valley, CA, 5Amgen, Inc., Thousand Oaks, CA, 6Amgen Inc., San Francisco, CA

    Background/Purpose: Data regarding the maintenance of disease activity (DA) and treatment persistence in patients (pts) who switched from combination therapy to monotherapy for the management…
  • Abstract Number: 1553 • ACR Convergence 2022

    Effectiveness and Safety of Adalimumab versus Leflunomide in Patients with Takayasu Arteritis – a Retrospective Cohort Study

    Faustino Peron Filho1, Andressa de Souza Moreira2, Anna Larissa Janes2 and Alexandre Wagner de Souza2, 1UNIFESP-EPM, Mogi das Cruzes, São Paulo, Brazil, 2UNIFESP-EPM, São Paulo, Brazil

    Background/Purpose: Therapy for Takayasu arteritis (TAK) is based on the combination of high-dose glucocorticoids and immunosuppressive and/or biologic agents. Patients presenting severe disease manifestations are…
  • Abstract Number: 0417 • ACR Convergence 2022

    Treating Spondyloarthritis Early: Does It Matter? Results from a Systematic Literature Review

    Dafne Capelusnik1, Diego Benavent2, Désirée van der Heijde3, Robert Landewé4, Denis Poddubnyy5, Astrid van Tubergen6, Louise Falzon7, Victoria Navarro-Compán8 and Sofia Ramiro9, 1Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, 2La Paz University Hospital, Madrid, Spain, 3Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 4Amsterdam University Medical Centers, Amsterdam, Netherlands, 5Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 6Maastricht UMC+, Maastricht, Netherlands, 7Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, 8Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 9Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: The ASAS-SPEAR (SPondyloarthritis EARly definition) project aims to develop a consensual definition of early SpA. Therefore, it is important to know whether treatment earlier…
  • Abstract Number: 2196 • ACR Convergence 2022

    Risk Factors for Severe COVID-19 Outcomes: A Study of Immune-mediated Inflammatory Diseases, Immunomodulatory Medications, Vaccination Status, and Comorbidities in a Large US Healthcare System

    Philip J Mease1, Qi Wei2, Michael Chiorean1, Lulu Iles-Shih1, Wanessa Matos2, Andrew Baumgartner2, Sevda Molani2, Yeon Mi Hwang2, Basazin Belhu2 and Jennifer Hadlock2, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Institute for Systems Biology, Seattle, WA

    Background/Purpose: Reported infection rates and severe outcomes of COVID-19 in patients with immune-mediated inflammatory diseases (IMIDs) and their therapy, have varied depending on the nature…
  • Abstract Number: 0418 • ACR Convergence 2022

    Real World Evidence on Disease Activity in Patients with Ankylosing Spondylitis Treated with Tumour Necrosis Factor Inhibitors and/or Nonsteroidal Anti-Inflammatory Drugs in Routine Care

    Jan Brandt-Juergens1, Judith Haschka2, Richard Finsterwalder3, Aurélie Casier4, Angela Kill5 and Stéphanie Dierckx6, 1Rheumatologische Schwerpunktpraxis, Berlin, Germany, 2Karl Landsteiner Institute for Gastroenterology and Rheumatology Rheuma-Zentrum Wien-Oberlaa, Vienna, Austria, 3Novartis Pharma GmbH, Vienna, Austria, 4N.V. Novartis Pharma S.A., Vilvoorde, Belgium, 5Novartis Pharma GmbH, Nuremberg, Germany, 6CHU UCL Namur- Site Godinne, Yvoir, Belgium

    Background/Purpose: Ankylosing Spondylitis (AS) is an inflammatory rheumatic disease affecting the axial skeleton (1), with a prevalence of up to 0.5% in Europe (2; 3),…
  • Abstract Number: 2215 • ACR Convergence 2022

    Reducing Cardiovascular Risk with Immunomodulators: A Single Blind Randomized Active Comparator Trial Among Patients with Rheumatoid Arthritis

    Daniel Solomon1, Jon Giles2, Katherine Liao1, Paul Ridker1, Pamela Rist1, Robert Glynn1, Rachel Broderick3, Fengxin Lu1, Meredith Murray1, Kathleen Vanni1, Leah Santacroce1, Shady Abohashem4, Philip Robson5, Zahi Fayad6, Venkatesh Mani5, Ahmed Tawakol4 and Joan Bathon7, 1Brigham and Women's Hospital, Boston, MA, 2Columbia University, New York, NY, 3Columbia University, Boston, MA, 4Massachusetts General Hospital, Boston, MA, 5Icahn School of Medicine at Mount Sinai, New York, NY, 6Mount Sinai, New York, NY, 7Columbia University Medical Center, New York, NY

    Background/Purpose: Recent large-scale randomized trials demonstrate that immunomodulators reduce the risk of cardiovascular (CV) events among the general population with atherosclerosis. However, it is uncertain…
  • Abstract Number: 0422 • ACR Convergence 2022

    Efficacy and Safety of Secukinumab in the Treatment of Axial Spondyloarthritis: Real-Life Data from TURKBIO Cohort

    Semih Gulle1, Ali Karakas1, Gercek Can2, Soner Senel3, Sedat Capar4, Huseyin ediz dalkilic5, Servet Akar6, Suleyman Serdar Koca7, Abdurrahman Tufan8, Ayten Yazici9, Sema Yilmaz10, Nevsun Inanc11, Merih Birlik1, Dilek Solmaz12, Ayse Cefle9, Berna Goker13, Servet Yolbas14, Niels Steen Krough15, Neslihan Yilmaz16, Sukran Erten17, Cemal Bes18, Ozgul Soysal19, Mehmet Akif Ozturk13, Seminur Haznedaroglu13, Sule Yavuz16, Haner Direskeneli20, Fatoş Onen21 and Ismail Sari22, 1Dokuz Eylul University School of Medicine Division of Rheumatology, Izmir, Turkey, 2Dokuz Eylul University School of Medicine Division of Rheumatology, Istanbul, Turkey, 3Erciyes University School of Medicine Division of Rheumatology, Kayseri, Turkey, 4Dokuz Eylul University Faculty of Science Department of Statistics, Izmir, Turkey, 5Uludag University School of Medicine Division of Rheumatology, Bursa, Turkey, 6Izmir Katip Celebi University School of Medicine, Izmir, Turkey, 7Firat University School of Medicine Division of Rheumatology, Elazıg, Turkey, 8Gazi University Medical Faculty Hospital, Istanbul, Turkey, 9Kocaeli University School of Medicine Division of Rheumatology, Kocaeli, Turkey, 10Selcuk University School of Medicine Division of Rheumatology, Konya, Turkey, 11Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, 12Kâtip Celebi University School of Medicine Division of Rheumatology, Izmir, Turkey, 13Gazi University School of Medicine Division of Rheumatology, Ankara, Turkey, 14Inonu University School of Medicine Division of Rheumatology, Malatya, Turkey, 15Zitelab Aps, Kopenhag, Denmark, 16Demiroglu Bilim University School of Medicine Division of Rheumatology, Istanbul, Turkey, 17Yildirim Beyazit University School of Medicine Division of Rheumatology, Ankara, Turkey, 18Basaksehir Cam and Sakura ospital, Division of Rheumatology, Istanbul, Turkey, 19Celal Bayar University, School of Medicine Division of Rheumatology, Manisa, Turkey, 20Marmara University School of Medicine Division of Rheumatology, Istanbul, Turkey, 21Dokuz Eylul University, Faculty of Medicine, Rheumatology, İzmir, Turkey, 22Dokuz Eylul University School of Medicine Division of Rheumatology, İzmir, Turkey

    Background/Purpose: In this study, we aimed to evaluate the results of secukinumab treatment in patients with Axial Spondyloarthritis (AxSpA) who were enrolled in the TURKBIO…
  • Abstract Number: 0424 • ACR Convergence 2022

    The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort

    Sadettin Uslu1, Semih Gulle1, Gercek Can2, Soner Senel3, Sedat Capar4, Huseyin ediz dalkilic5, Servet Akar6, Suleyman Serdar Koca7, Abdurrahman Tufan8, Ayten Yazici9, Sema Yilmaz10, Nevsun Inanc11, Merih Birlik1, Dilek Solmaz12, Ayse Cefle9, Berna Goker13, Servet Yolbas14, Niels Steen Krough15, Neslihan Yilmaz16, Sukran Erten17, Cemal Bes18, Ozgul Soysal19, Mehmet Akif Ozturk13, Seminur Haznedaroglu13, Sule Yavuz16, Haner Direskeneli20, Fatoş Onen21 and Ismail Sari22, 1Dokuz Eylul University School of Medicine Division of Rheumatology, Izmir, Turkey, 2Dokuz Eylul University School of Medicine Division of Rheumatology, Istanbul, Turkey, 3Erciyes University School of Medicine Division of Rheumatology, Kayseri, Turkey, 4Dokuz Eylul University Faculty of Science Department of Statistics, Izmir, Turkey, 5Uludag University School of Medicine Division of Rheumatology, Bursa, Turkey, 6Izmir Katip Celebi University School of Medicine, Izmir, Turkey, 7Firat University School of Medicine Division of Rheumatology, Elazıg, Turkey, 8Gazi University Medical Faculty Hospital, Istanbul, Turkey, 9Kocaeli University School of Medicine Division of Rheumatology, Kocaeli, Turkey, 10Selcuk University School of Medicine Division of Rheumatology, Konya, Turkey, 11Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, 12Kâtip Celebi University School of Medicine Division of Rheumatology, Izmir, Turkey, 13Gazi University School of Medicine Division of Rheumatology, Ankara, Turkey, 14Inonu University School of Medicine Division of Rheumatology, Malatya, Turkey, 15Zitelab Aps, Kopenhag, Denmark, 16Demiroglu Bilim University School of Medicine Division of Rheumatology, Istanbul, Turkey, 17Yildirim Beyazit University School of Medicine Division of Rheumatology, Ankara, Turkey, 18Basaksehir Cam and Sakura ospital, Division of Rheumatology, Istanbul, Turkey, 19Celal Bayar University, School of Medicine Division of Rheumatology, Manisa, Turkey, 20Marmara University School of Medicine Division of Rheumatology, Istanbul, Turkey, 21Dokuz Eylul University, Faculty of Medicine, Rheumatology, İzmir, Turkey, 22Dokuz Eylul University School of Medicine Division of Rheumatology, İzmir, Turkey

    Background/Purpose: In this study, it was aimed to evaluate the long-term drug survival, efficacy and safety of infliximab biosimilar CT-P13 in Turkish patients diagnosed with…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences